Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

FDA rejects Ocular Therapeutix eye drug, citing manufacturing issues

  • Adam Feuerstein

By Adam Feuerstein July 11, 2017

Reprints
FDA; Drug Administration campus
Andrew Harnik/AP

Ocular Therapeutix failed for a second time to secure approval of its eye drug Dextenza. On Tuesday, the FDA rejected the drug, citing unresolved problems with manufacturing and quality control testing.

Shares of Ocular were halted at $7.60 in Tuesday’s after-market session. The company has approximately $2 per share in cash on hand.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

‘Three Identical Strangers’: It’s not too late to address…
‘Three Identical Strangers’: It’s not too late to address the ethical violations
5 reasons why no one has built a better…
5 reasons why no one has built a better EpiPen
Watch: P-value, an important measurement in clinical trials, explained
Watch: P-value, an important measurement in clinical trials, explained
Moderna CEO made $398 million in 2022, but still…
Moderna CEO made $398 million in 2022, but still pledges to give most to charity
Pharmalittle: Sanofi cuts price on a popular insulin by…
Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too…
FDA to convene advisory panel for Sarepta’s gene therapy…
FDA to convene advisory panel for Sarepta’s gene therapy for Duchenne

Recommended Stories